Diseases

Eli Lilly and Company proclaimed that the USFood and Drug Administration has sanctioned Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based…
Read More...

PharmaCyte Biotech aiming to develop targeted cellular therapies for Cancer and diabetes using its signature  live-cell encapsulation technology, Cell-in-a-Box, announced that its…
Read More...

Therapy combinations, Biomarkers and the challenge of prayer coverage for CAR T-cell therapy are the topics selected for this year's special tissue on immuno-oncology in  Evidence-Based…
Read More...

Genomic Health asserted the U.S commercial launch of  Oncotype DX AR-V7 Nucleus Detect test. The Oncotype DX AR-V7 Nucleus Detect test was developed by Epic Sciences to help prolong the…
Read More...

The Journal of the American Osteopathic Association signified inefficiency of Vitamin D that can't be metabolized owing to low Magnesium Levels that implies Vitamin D remains stored and…
Read More...

CE Mark approval was sought for EPD's Cardiac Mapping and Navigation System. The system helps electrophysiologists navigate the heart by generating a succinct 3D Map while imaging and…
Read More...

Leading Science and technology company, Merck announced that the Argentinian Administration of Medicines, Food and Medical Technology has sanctioned the registration of MAVENCLAD …
Read More...

Atrium Health's Levine Children's Hospital proved to be a new trial site to test a new medicine for children that can regulate and stabilize their blood pressure in fatal circumstances.…
Read More...

Amgen asserted that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for…
Read More...

Jazz Pharmaceuticals asserted the enrollment of patients in a Phase 2 Clinical Trial evaluating the efficacy and safety of defibrotide for the prevention of acute…
Read More...

Stephen Ostroff, M.D., Deputy Commissioner for Foods and Veterinary Medicine on National Toxicology Program draft report on Bisphenol A stating that "We base our regulatory decisions on…
Read More...

Pfizer claimed the appointment of Albert Bourla, DVM,Ph.D to its Board off Directors with effect from immediately. Dr.Albert Bourla is currently the Chief operating officer of…
Read More...

Alfa Scientific Designs, the US manufacturer of rapid, point-of care medical devices asserted that the FDA has extended the 510(k) clearance for  ALFA's iFOB with Driven Flow…
Read More...

MabSpace Biosciences declares FDA cleared investigational New Drug for MSB2311 which is a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with…
Read More...

Surgical guidance company, Endomag asserted that it has sought 510 (k) clearance from the US Food and Drug Administration to further extend the indication of its Magseed magnetic marker…
Read More...

Kadmon Holdings claimed positive results from ongoing Phase 2 Clinical trial KD025-208 assessing updated optimistic results from an ongoing Phase 2 Clinical Trial KD025-208 evaluating…
Read More...

Puma Biotechnology asserted that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion thereby refuting to grant Marketing…
Read More...

Pfizer asserted that the Committee for Medicinal Products for human use of the European Medicines Agency has disapproved of expanding use of SUTENT to encompass the adjuvant treatment…
Read More...

CEL-SCI Corporation asserted that it was extending the expiration date of its Series DD and Series EE warrants to July 1, 2018. The Series DD and Series EE warrants were issued on…
Read More...

Pfizer asserted that that the Committee for Medicinal products for Human use of the European Medicines Agency has adopted positive opinions extending marketing authorizations in the EU…
Read More...